GSA CAPITAL PARTNERS LLP

Position in RLMD — Relmada Therapeutics, Inc.

CIK 1362033 LONDON, X0

Position in RLMD

as of Mar 31, 2026 · filed May 8, 2026 Compact

Position Value

$136,179

+$71,298 QoQ

Shares Held

19,566

-84.3% QoQ

Ownership

0.019%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Dec 2021

11 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Healthcare · as of Mar 31, 2026

GSA CAPITAL PARTNERS LLP holds $100,995,552 across 161 Biotechnology names. RLMD ranks #134 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	REGN	Regeneron Pharmaceuticals, Inc.	3,831	$2,959,983
2	ARDX	Ardelyx, Inc.	473,061	$2,833,635
3	NTLA	Intellia Therapeutics, Inc.	178,301	$2,285,818
4	NUVB	Nuvation Bio Inc.	495,792	$2,126,947
5	RXRX	Recursion Pharmaceuticals, Inc.	669,568	$2,055,573
6	WVE	Wave Life Sciences Ltd.	282,719	$2,049,712
7	SRPT	Sarepta Therapeutics, Inc.	90,960	$1,979,289
8	IOVA	Iovance Biotherapeutics, Inc.	557,085	$1,955,368

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$136,179	19,566	-84.3%	Shares	Sole	2026-05-08
2024-12-31	$64,881	124,773	+15.1%	Shares	Sole	2025-02-07
2024-09-30	$351,254	108,412	+0.3%	Shares	Sole	2024-11-05
2024-06-30	$324,345	108,115	+4.6%	Shares	Sole	2024-08-15
2024-03-31	$480,442	103,321	-44.0%	Shares	Sole	2024-05-03
2023-12-31	$764,132	184,573	-5.5%	Shares	Sole	2024-02-16
2023-09-30	$586,245	195,415	-28.0%	Shares	Sole	2023-11-15
2023-06-30	$667,949	271,524	+333.8%	Shares	Sole	2023-08-14
2023-03-31	$141,471	62,598	-48.9%	Shares	Sole	2023-05-12
2022-12-31	$427,839	122,590	+603.4%	Shares	Sole	2023-02-13
2021-12-31	$392,675	17,429	—	Shares	Sole	2022-02-14
No filing history on record for this holder in this stock.